49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
Showing 1 to 10 of 19 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05666336 (ClinicalTrials.gov) | December 31, 2022 | 8/12/2022 | Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients | Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of ... | Systemic Lupus Erythematosus | Biological: Telitacicept;Drug: Hydroxychloroquine;Drug: Prednisone;Drug: Methylprednisolone;Drug: Cyclophosphamide;Drug: Mycophenolate Mofetil;Drug: Tacrolimus Biological: Telitacicept;Drug: Hydroxychloroquine;Drug: Prednisone;Drug: Methylprednisolone;Drug: Cy ... | Fen Li | NULL | Not yet recruiting | 18 Years | 75 Years | All | 30 | Phase 4 | NULL |
| 2 | JPRN-jRCTs021210042 | 14/10/2021 | 14/10/2021 | Randomized , double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab for early systemic lupus erythematosus Randomized , double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and saf ... | Randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab for early systemic lupus erythematosus - BEFORE-S Randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safe ... | Systemic Lupus Erythematosus : SLE Systemic Lupus Erythematosus, SLE;D008180 | Group A to which the test drug is administered and Group B to which the placebo is administered will be set. Group A: In addition to the usual treatment, belimumab (GlaxoSmithKline Co., Ltd., trade name Benlysta) will be administered subcutaneously once a week at 200 mg. Administration will be continued for 24 weeks. Group B: Placebo will be administered and standard of care will be performed. Both groups will receive a combination of hydroxychloroquine unless there is a reason not to use hydroxychloroquine as usual treatment. If the attending physician determines that it is not appropriate to administer the study drug, the attending physician will not administer the study drug during the week and will record the reason Group A to which the test drug is administered and Group B to which the placebo is administered will ... | Ishii Tomonori | NULL | Recruiting | >= 20age old | < 80age old | Both | 30 | N/A | Japan |
| 3 | ITMCTR2100005063 | 2021-07-15 | 2021-07-16 | A prospective non-randomized controlled study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus A prospective non-randomized controlled study of integrated traditional Chinese and western medicine ... | A prospective cohort study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus A prospective cohort study of integrated traditional Chinese and western medicine for moderately act ... | Systemic lupus erythematosus | Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome differentiation;Control Group:Western Medicine (glucocorticoid, hydroxychloroquine, methotrexate, azathioprine or cyclophosphamide); Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome ... | Zhejiang Chinese Medical University | NULL | Pending | 18 | 65 | Female | Experimental group:264;Control Group:264; | N/A | China |
| 4 | ChiCTR2100048796 | 2021-07-15 | 2021-07-16 | A prospective non-randomized controlled study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus A prospective non-randomized controlled study of integrated traditional Chinese and western medicine ... | A prospective cohort study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus A prospective cohort study of integrated traditional Chinese and western medicine for moderately act ... | Systemic lupus erythematosus | Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome differentiation;Control Group:Western Medicine (glucocorticoid, hydroxychloroquine, methotrexate, azathioprine or cyclophosphamide); Experimental group:Western medicine + Jiedu Quyu Zishen Fang's modified treatment based on syndrome ... | Zhejiang Chinese Medical University | NULL | Pending | 18 | 65 | Female | Experimental group:264;Control Group:264; | N/A | China |
| 5 | ChiCTR1900022934 | 2019-06-20 | 2019-05-04 | Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus eryth ... | Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus eryth ... | Systemic Lupus Erythematosus | Experimental group:Langchuangjing granule + Prednisone acetate tablets, Hydroxychloroquine;control group:Prednisone acetate tablets?Hydroxychloroquine;healthy control group:nothing; Experimental group:Langchuangjing granule + Prednisoneacetatetablets, Hydroxychloroquine;control gro ... | Nanjing University of Chinese Medicine Affiliated Hospital | NULL | Pending | Both | Experimental group:20;control group:20;healthy control group:20; | Phase 1 | China | ||
| 6 | ITMCTR1900002316 | 2019-06-20 | 2019-05-04 | Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus eryth ... | Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus eryth ... | Systemic Lupus Erythematosus | healthy control group:nothing;control group:Prednisone acetate tablets\Hydroxychloroquine;Experimental group:Langchuangjing granule + Prednisone acetate tablets, Hydroxychloroquine; healthy control group:nothing;control group:Prednisoneacetatetablets\Hydroxychloroquine;Experimental ... | Nanjing University of Chinese Medicine Affiliated Hospital | NULL | Pending | Both | healthy control group:20;control group:20;Experimental group:20; | Phase 1 | China | ||
| 7 | ChiCTR1800020286 | 2019-02-01 | 2018-12-22 | Clinical evaluation of the application of Langchuangjing granule in the treatment of systemic lupus erythematosus Clinical evaluation of the application of Langchuangjing granule in the treatment of systemic lupus ... | Efficacy and safety of Langchuangjing granule in the treatment of systemic lupus erythematosus: a clinical evaluation Efficacy and safety of Langchuangjing granule in the treatment of systemic lupus erythematosus: a cl ... | Systemic Lupus Erythematosus | Group 2:Langchuangjing granule + Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks.;Group 1:Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks.; Group 2:Langchuangjing granule + Prednisoneacetatetablets, hydroxychloroquineand other Western medic ... | Nanjing University of Chinese Medicine Affiliated Hospital | NULL | Pending | Both | Group 2:40;Group 1:20; | I (Phase 1 study) | China | ||
| 8 | ChiCTR1800019308 | 2018-11-12 | 2018-11-04 | Efficacy and tolerability of multitarget therapy with NHMX for systemic lupus erythematosus | Efficacy and tolerability of multitarget therapy with NHMX for systemic lupus erythematosus | systemic lupus erythematosus | NHMX:One kind of non-steroid anti-inflammatory drugs combines with hydroxychloroquine sulfate(=200mg/bid) and methotrexate(7.5-20mg/w), with addition of glucocorticoid (=0.5mg/kg·d) or cyclosporine (maintaining the drug concentration between 30-90ug/l);control:hydroxychloroquine sulfate(=200mg/bid) and methotrexate(7.5-20mg/w), with addition of glucocorticoid (=0.5mg/kg·d) or cyclosporine(maintaining the drug concentration between 30-90ug/l); NHMX:One kind of non-steroid anti-inflammatory drugs combines with hydroxychloroquine sulfate(=200mg ... | The Third Affiliated Hospital, Southern Medical University | NULL | Recruiting | 18 | 65 | Both | NHMX:75;control:75; | China | |
| 9 | NCT03030118 (ClinicalTrials.gov) | December 28, 2017 | 15/1/2017 | Study of Anti-Malarials in Incomplete Lupus Erythematosus | Study of Anti-Malarials in Incomplete Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: Hydroxychloroquine;Drug: Placebo Oral Capsule | Milton S. Hershey Medical Center | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Active, not recruiting | 15 Years | 49 Years | All | 187 | Phase 2 | United States |
| 10 | NCT03122431 (ClinicalTrials.gov) | June 5, 2017 | 17/4/2017 | Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases | Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmun ... | Systemic Lupus Erythematosus (SLE);Juvenile SLE;Cutaneous Lupus | Drug: Thalidomide;Drug: Hydroxychloroquine reduced;Drug: standard dose of HCQ | University of Sao Paulo General Hospital | Fundação de Amparo à Pesquisa do Estado de São Paulo | Completed | 5 Years | 64 Years | All | 93 | Phase 4 | Brazil |